Artiva Biotherapeutics, Inc. (ARTV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 14.58M USD | Liabilities, Current |
| Cash and equivalents | 301.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $14.58M | $301.45M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $10.88M | $20.95M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $13.09M | $26.70M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $11.12M | $25.51M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $10.77M | $28.47M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $12.20M | $30.40M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $12.25M | $40.23M | (m) | $0.00 | (m) | (m) |
| 2024-09-30 | (m) | $13.29M | $55.88M | (m) | $569.00K | (m) | (m) |
| 2024-06-30 | (m) | $10.83M | $34.25M | (m) | $569.00K | (m) | (m) |
| 2024-03-31 | (m) | (m) | $48.20M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $12.23M | $53.50M | (m) | $1.03M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $65.89M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $53.70M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |